RT Journal Article
SR Electronic
T1 Comparative validation of the BOADICEA and Tyrer-Cuzick breast cancer risk models incorporating classical risk factors and polygenic risk in a population-based prospective cohort
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.27.20081265
DO 10.1101/2020.04.27.20081265
A1 Choudhury, Parichoy Pal
A1 Brook, Mark N.
A1 Wilcox, Amber N.
A1 Lee, Andrew
A1 Mulder, Charlotta
A1 Coulson, Penny
A1 Schoemaker, Minouk J.
A1 Jones, Michael E.
A1 Swerdlow, Anthony J.
A1 Chatterjee, Nilanjan
A1 Antoniou, Antonis C.
A1 Garcia-Closas, Montserrat
YR 2020
UL http://medrxiv.org/content/early/2020/05/04/2020.04.27.20081265.abstract
AB Purpose The Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm (BOADICEA) and the Tyrer-Cuzick breast cancer models have recently been extended to include polygenic risk scores (PRS). In addition, BOADICEA has also been extended to include reproductive and lifestyle factors, which were already part of Tyrer-Cuzick model. We conducted a comparative validation of the extended models including a recently developed 313-variant PRS in a population-based prospective cohort.Methods We used data from a nested case-control sample of 1,337 women of European ancestry (619 incident breast cancer cases) aged 23-75 years from the Generations Study. Models were evaluated for calibration of five-year absolute risk and risk discrimination.Results The extended BOADICEA model with risk factors and PRS was well calibrated across risk deciles: expected-to-observed ratio (E/O) at the highest risk decile = 0.97 (95% Cl = 0.51 to 1.86) for women younger than 50 years and 1.09 (0.66 to 1.80) for women 50 years or older. Adding risk factors and PRS to the BOADICEA model improved discrimination modestly in younger women (Area Under the Curve (AUC): 69.7% vs. 69.1%) and substantially in older women (AUC: 64.6% vs. 56.8%). The Tyrer-Cuzick model with PRS had similar discrimination as the extended BOADICEA model for both age groups; but showed evidence of overestimation at the highest risk decile: E/O=1.54 (0.81 to 2.92) for younger and 1.73 (1.03 to 2.90) for older women.Conclusion The extended BOADICEA model identified women in a European ancestry population at elevated breast cancer risk more accurately than the Tyrer-Cuzick model with PRS. These analyses can inform choice of risk models for risk stratified breast cancer prevention for women of European ancestry.Competing Interest StatementBreast and Ovarian Analysis of Disease and Carrier Estimation Algorithm (BOADICEA) has been licensed to Cambridge Enterprise (University of Cambridge) and Antonis C. Antoniou and Andrew Lee are listed as creators. No other disclosures are reported.Funding StatementThis work was supported by Cancer Research UK grants C12292/A20861 and C1287/A16563; the European Union’s Horizon 2020 research and innovation programme under grant agreement number 633784 (B-CAST). The Generations Study acknowledge Breast Cancer Now and the Institute of Cancer Research for support and funding of the Generations Study, and the study participants, study staff, and the doctors, nurses and other healthcare staff and data providers who have contributed to the study. The Institute of Cancer Research acknowledge National Health Service funding to the National Institute for Health Research Biomedical Research Center, UK. The works of Parichoy Pal Choudhury, Montserrat Garcia-Closas were supported by the Intramural Research Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services. The work of Amber N. Wilcox is supported by the University of North Carolina LCCC Cancer Control Education Program predoctoral training grant from the National Cancer Institute (T32-CA057726). The work of Nilanjan Chatterjee was supported by the Patient Centered Outcomes Research Institute (PCORI) Award (ME1602-34530).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesN/A